Log in

Neuro Price, News and Analysis (NRO)

Neuro logo
$0.0001
0.0000 (0.00%)
(As of 09/30/2019 06:07 PM ET)
Add
1-Hour Price Change 0.00%
1-Day Price Change 0.00%
7-Day Price Change -15.17%
1-Day Volume$0.00
Market Cap$5,036.00
BTC Price0.00000001 BTC
Circulating Supply59.40 million
Total Supply61.40 million
Maximum SupplyN/A

About Neuro (NRO)

Currency Details

Name Neuro
SymbolNRO
Market Capitalization$5,036.00
Coin or TokenCoin
Algorithm SHA-256
Proof TypePoW/PoS
Genesis Date5/30/2017
Mineable?No
Number of Exchanges1

Official Links

Official Websiteneurocoin.org
Official Website (Alt)N/A
BitcoinTalk AnnouncementView
Twitter Account@neurocoinnews
Facebook PageN/A
Github AccountView

Community Discussion

Reddit CommunityN/A
Telegram GroupView
Discord GroupN/A
Message BoardN/A
Message Board (Alt)N/A

Research Tools

Blockchain Explorerchainz.cryptoid.info
Blockchain Explorer (Alt)N/A
CoinMarketCapView
CryptoCompareView
CoinGeckoView

Receive NRO News and Prices via Email

Sign-up to receive the latest news and price data for Neuro and its competitors with MarketBeat's CryptoBeat newsletter.

Neuro (NRO) Frequently Asked Questions

What exchanges can I buy or trade Neuro on?

Neuro can be purchased or sold on the following cryptocurrency exchanges: CoinExchange.

How do I buy Neuro?

It is not possible to buy most cryptocurrencies with U.S. dollars. Bitcoin, Bitcoin Cash, Ethereum and Litecoin can be purchased with U.S. dollars using Coinbase. Once you have purchased Bitcoin using Coinbase, you can then transfer your Bitcoin to an exchange such as Binance or Changelly to purchase other cryptocurrencies, including Neuro.

Where can I get Neuro wallet?

Neuro produces its own wallet software that is available for download on its website, which allows you to store Neuro on your computer. For maximum security, you can store your cryptocurrencies on a dedicated hardware wallet such as a TREZOR wallet or a Ledger Nano S. If you do not wish to buy a hardware wallet, you may consider using a mobile wallet such as Atomic Wallet, Jaxx, or Coinomi to store multiple cryptocurrencies with some added security benefits.

What is the value of Neuro?

One Neuro (NRO) is currently worth $0.00 on major cryptocurrency exchanges. You can also exchange one Neuro for 0.00000001 bitcoin(s) on major exchanges. The value (or market capitalization) of all available Neuro in U.S. dollars is $5,036.00.

What hashing algorithm does Neuro use?

Neuro is a proof of work (PoW) and proof of stake (PoS) coin that uses the SHA-256 algorithm.

How do I mine Neuro?

Neuro and other SHA-256 coins can typically only be mined profitably with a piece of specialized mining hardware called an ASIC, which stands for application-specific integrated circuit. Major manufacturers of ASICs include BitMain (AntMiner), Butterfly Labs, Canaan (AvalonMiner), FutureBit and GridSeed. ASIC hardware can be purchased directly from the manufacturer or from resellers on Amazon and eBay.

What coins are similar to Neuro?

The following coins use the same hashing algorithm (SHA-256) as Neuro: StrongHands, PetroDollar, Ixcoin, Freicoin, BUZZCoin, SixEleven, GlobalToken, Version, Deutsche eMark, PayCoin, Acoin, Californium, Eurocoin, Zayedcoin and ARbit.

What is the Reddit page for Neuro?

The official Reddit community (subreddit) for Neuro is N/A.


MarketBeat Community Rating for Neuro (NRO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Neuro and other cryptocurrencies. Vote "Outperform" if you believe the stock will outperform other cryptocurrencies over the long term. Vote "Underperform" if you believe the stock will underperform other cryptocurrencies over the long term. You may vote once every thirty days.

Chart

Neuro (NRO) Price Chart for Monday, October, 21, 2019

Loading chart…

Google Trends

Neuro (NRO) Search Trends

There is a correlation between price appreciation and public interest in cryptocurrencies, such as Neuro. Many cryptocurrency investors use Google Trends, which measures the volume of web searches for a particular topic over time, as a tool to gauge whether public interest is increasing or decreasing for a particular cryptocurrency. The chart below shows how search volume has changed for the phrase "Neuro Coin" over the last 90 days.



Neuro (NRO) Social Media Trends

Headlines

Neuro (NRO) News Headlines

DateHeadline
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma EarningsThe Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
www.benzinga.com - October 13 at 6:08 PM
Blackrock Microsystems’ BCI Technology Selected for Collaboration with Republic of PolandBlackrock Microsystems’ BCI Technology Selected for Collaboration with Republic of Poland
www.prweb.com - September 17 at 1:29 PM
360 Neuro Health Institute Co-hosted with Dell Childrens Medical Center of Central Texas will Host the 2019 Concussion Health Summit and Town Hall Event360 Neuro Health Institute Co-hosted with Dell Children's Medical Center of Central Texas will Host the 2019 Concussion Health Summit and Town Hall Event
www.prweb.com - September 10 at 6:31 AM
argenx reports first quarter 2018 financial results and provides business updateargenx reports first quarter 2018 financial results and provides business update
feeds.benzinga.com - May 9 at 3:13 AM
Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat NeuroblastomaCellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma
markets.financialcontent.com - May 2 at 8:04 AM
NICO Continues to Innovate with Smallest Trans-Sulcal Brain Access Tool in the WorldNICO Continues to Innovate with Smallest Trans-Sulcal Brain Access Tool in the World
www.prnewswire.com - May 1 at 2:14 PM
NeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York CityNeuroMetrix, Inc. to Participate in Upcoming Disruptive Growth & Healthcare Conference in New York City
feeds.benzinga.com - May 1 at 11:53 AM
Top Innovations in Stretchable Biosensors, Implantable Neurostimulators, Needle-free Vaccine Delivery, and Nanomaterials - ResearchAndMarkets.comTop Innovations in Stretchable Biosensors, Implantable Neurostimulators, Needle-free Vaccine Delivery, and Nanomaterials - ResearchAndMarkets.com
markets.financialcontent.com - April 30 at 6:36 PM
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual MeetingACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
markets.financialcontent.com - April 27 at 8:08 AM
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body RegionsNeurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
www.prnewswire.com - April 25 at 8:31 PM
Preliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual MeetingPreliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at the American Academy of Neurology Annual Meeting
www.prnewswire.com - April 24 at 9:03 PM
MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with AdditiMediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additi
markets.financialcontent.com - April 24 at 7:01 AM
Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada® (alemtuzumab) in Clinical TrialsTreatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada® (alemtuzumab) in Clinical Trials
markets.financialcontent.com - April 23 at 9:36 AM
Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic MeetingEvolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic Meeting
markets.financialcontent.com - April 23 at 7:31 AM
Sensorion’s SENS-401 Reduces Hearing Loss in Preclinical Study When Oral Administration Initiated Up to Four Days after Acoustic TraumaSensorion’s SENS-401 Reduces Hearing Loss in Preclinical Study When Oral Administration Initiated Up to Four Days after Acoustic Trauma
markets.financialcontent.com - April 23 at 1:51 AM
New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple SclerosisNew OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
markets.financialcontent.com - April 23 at 1:51 AM
Akcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 American Academy of Neurology Annual MeetingAkcea Therapeutics to Present Data on Inotersen for the Treatment of hATTR Amyloidosis at the 2018 American Academy of Neurology Annual Meeting
markets.financialcontent.com - April 21 at 1:17 PM
InspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, PolandInspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland
feeds.benzinga.com - April 19 at 7:34 AM
Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los AngelesBiohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
www.prnewswire.com - April 19 at 3:48 AM
Preliminary Study Suggests Drug May Help Babies with Spinal Muscular AtrophyPreliminary Study Suggests Drug May Help Babies with Spinal Muscular Atrophy
www.prnewswire.com - April 18 at 7:46 PM
Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New MexicoEndonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico
markets.financialcontent.com - April 18 at 10:13 AM
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the 2018 American Academy of Neurology Annual MeetingGW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the 2018 American Academy of Neurology Annual Meeting
markets.financialcontent.com - April 12 at 7:31 AM
NeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference CallNeuroMetrix, Inc. Announces Date for 2018 First Quarter Financial Results Conference Call
feeds.benzinga.com - April 11 at 11:16 AM
TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring CongressTRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
feeds.benzinga.com - April 5 at 7:55 AM
ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of ManufacturingProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
www.prnewswire.com - April 3 at 7:51 AM
ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory BoardProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board
www.prnewswire.com - March 20 at 8:12 AM
Strongbridge Biopharma plc to Present KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American Academy of Neurology Annual MeetingStrongbridge Biopharma plc to Present KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis Data at the 2018 American Academy of Neurology Annual Meeting
markets.financialcontent.com - March 5 at 7:59 AM
Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS ConferenceLexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
markets.financialcontent.com - February 28 at 7:13 AM
Takeda Deepens Commitment to Develop Innovative Treatments for Neurological DiseasesTakeda Deepens Commitment to Develop Innovative Treatments for Neurological Diseases
markets.financialcontent.com - February 20 at 7:58 AM
Ekso Bionics® to Expand Clinical Trial Sites for Comparative Multicenter WISE StudyEkso Bionics® to Expand Clinical Trial Sites for Comparative Multicenter WISE Study
markets.financialcontent.com - February 12 at 8:01 AM
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results
www.prnewswire.com - February 6 at 1:28 PM
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program MilestonesNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
www.prnewswire.com - January 7 at 2:10 PM
Neurocrine Biosciences Announces Retirement of Christopher OBrien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical OfficerNeurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer
www.prnewswire.com - January 7 at 2:10 PM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and TechnologyNeuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
feeds.benzinga.com - January 5 at 6:50 PM
13G Filing: Sabby Capital and Neurometrix Inc. (NURO)13G Filing: Sabby Capital and Neurometrix Inc. (NURO)
feedproxy.google.com - January 4 at 1:40 PM
NeuroMetrix CEO to Participate in CES 2018 Panel on Opioid CrisisNeuroMetrix CEO to Participate in CES 2018 Panel on Opioid Crisis
markets.financialcontent.com - January 4 at 11:04 AM
NeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase ConferencesNeuroMetrix to Present at Upcoming Biotech Showcase and Digital Medicine Showcase Conferences
feeds.benzinga.com - January 3 at 12:26 PM

This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel